MedTech Strategist Issue: Vol. 5, No. 6 - May 11, 2018


Already a Subscriber?


Not a Subscriber?


Executive Interview: "ExploraMed: Patient Need, Stakeholder Perspective Guide the Design of Solutions"

By David Cassak, Co-Editor-in-Chief

A conversation with the founders of MedTech incubator ExploraMed, which for the past 20 years has been behind some of the most innovative technologies in medical devices and, just as importantly, some of the most successful. ExploraMed’s track record underscores the importance of team work, with teams that embrace not just technology developers, but the investors and executives who help bring that technology to the patient.

Surgical Pain Management - "Spine Surgeons Confront the Opioid Crisis"

By Wendy Diller, Senior Writer/Market Analyst

The opioid crisis is one of the biggest public health problems of this generation, and spine surgeons—indeed all orthopedic surgeons—are at the forefront of its challenges. 



Q1 M&A/Financing Wrap-Up: "Despite Optimistic Outlook, M&A Dries Up and IPOs Remain Non-Existent"

By Stephen Levin, Co-Editor-in-Chief

Coming out of last year, all of the signs pointed to a robust first quarter with continued strong M&A and a resurgence in IPOs. The results defied expectations: a decline in M&A valuation, no IPOs and a drop in follow-on offerings. Yet, the macro environment remains strong, providing a cause for optimism for the rest of 2018.

Market Brief: "Early Q1 Data Shows Pressure on Ortho"

By Wendy Diller, Senior Writer/Market Analyst

In an industry where small shifts in growth rates count, the orthopedics industry continues to be under pressure, based on Q1 results. Its two largest subsectors, recon and spine, saw growth rates decline, due to the acceleration of negative drivers. Trauma and extremities are bright spots, but they account for much smaller percentages of total overall revenues.



Start-Ups To Watch - "Humacyte: Bioengineered Human Blood Vessel Enters Pivotal Trials"

By Mary Stuart, Senior Writer/Market Analyst

Humacyte is working toward its vision of enabling surgeons in the OR to reach for a tissue-engineered blood vessel as easily as they’d reach for forceps. 

Start-Ups To Watch: XableCath: Peripheral Vascular Care, Reimagined

By Colin Miller

XableCath has developed a low cost, manual metal-tipped over-the-wire catheter designed to remain in the true lumen of the artery. The start-up positions it as the treatment of first resort for complex lesions like severe and chronic total occlusions in the peripheral vasculature. 


Not a Subscriber?

Already a Subscriber?

Want a Sample Article?

Companies Covered in this Issue: Abiomed Inc., Baxter International Inc., Boston Scientific Corp., CR Bard Inc., Coloplast AS, Edwards Lifesciences Corp., ExploraMed LLC, Humacyte Inc., Illumina Inc., Intuitive Surgical Inc., Johnson & Johnson, LifeScan Inc., LivaNova PLC, Mallinckrodt PLC, Medtronic PLC, MoxiMed Inc., NxThera Inc., Smith & Nephew PLC, Stanford University, Stryker Corp., TandemLife, ValleyLab Inc., Vyaire Medical, Willow, XableCath Inc., Zimmer Biomet Holdings Inc.

Topics Covered in this Issue: Cardiovascular/Vascular, Executive Interviews, Investment/Finance/M&As, Medtech Business Strategies/Development, Orthopedics/Spine, Pain Management, Pharmaceuticals, Regenerative Medicine/Cell Therapy, Respiratory, Start-Ups, Surgery/Minimally Invasive Surgery/Robotics, Urology/Renal Disease, Women’s Health